Arixtra is indicated to treat prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip fracture surgery, including extended prophylaxis, hip replacement surgery, knee replacement surgery or abdominal surgery who are at risk for thromboembolic complications.
Under an interim distribution arrangement with Aspen, Mylan is already selling Arixtra in the US, while Apotex is currently selling the AG of Arixtra, which will be transitioning to Mylan Institutional by end of 2014.
Mylan CEO Heather Bresch said DVT/PE is a serious health concern that is estimated to affect up to 600,000 people in the US.
"The addition of Arixtra is an attractive opportunity to broaden the range of therapeutic categories we market in the US, in both the hospital and retail settings, and bolster our growing portfolio of complex injectables to better meet our customers’ needs," Bresch said.
As part of the deal, Mylan will pay Aspen $225m upon completion of the transaction, which is subject to regulatory clearances.
The company said that an additional $75m will be held in escrow and released upon satisfaction of certain conditions.
The deal will see Aspen supply Arixtra and the AG of Arixtra to Mylan, subject to certain terms and conditions.